Upstream Bio, Inc. (UPB)
NASDAQ:UPB
Want to see UPB full AI Analyst Report?
Top Page
Upstream Bio, Inc.
(NASDAQ:UPB)
Select Model
Select Model
Rating:48Neutral
Price Target:
$9.50
▼(-68.65% Downside)
Action:Reiterated
Date:05/14/26
The score is held back primarily by heavy losses and accelerating cash burn, plus weak longer-term technical trends (below 100/200-day averages). These negatives are partially offset by a strong, low-debt balance sheet that provides financial flexibility; valuation is hard to anchor due to negative earnings and no indicated dividend yield.
Positive Factors
Balance sheet strength
Very low leverage and a large equity base provide durable financial flexibility to fund multi-year clinical programs, absorb trial setbacks, and negotiate partnerships. This structural strength extends runway options and reduces refinancing pressure while the firm advances late-stage development.
Negative Factors
High and worsening cash burn
Material and accelerating cash consumption is a persistent structural risk for a clinical-stage biotech that must fund trials and development. Unless spending is reduced or new funding secured, burn will constrain development choices and force dilutive or restrictive financing decisions within months.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet strength
Very low leverage and a large equity base provide durable financial flexibility to fund multi-year clinical programs, absorb trial setbacks, and negotiate partnerships. This structural strength extends runway options and reduces refinancing pressure while the firm advances late-stage development.
Read all positive factors
Upstream Bio, Inc. (UPB) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$455.50M
Dividend YieldN/A
Average Volume (3M)388.50K
Price to Earnings (P/E)―
Beta (1Y)1.04
Revenue GrowthN/A
EPS GrowthN/A
CountryUS
Employees52
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-2.91
Shares Outstanding54,419,987
10 Day Avg. Volume473,530
30 Day Avg. Volume388,499
Financial Highlights & Ratios
PEG Ratio-0.13
Price to Book (P/B)4.30
Price to Sales (P/S)512.30
P/FCF Ratio-10.97
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue108.33
Enterprise Value/Gross Profit109.96
Enterprise Value/Ebitda-2.10
Forecast
1Y Price Target
$45.00Price Target Upside48.51% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
EPS Forecast (FY)-2.89
Revenue Forecast (FY)$1.69M
Upstream Bio, Inc. Business Overview & Revenue Model
Company Description
Upstream Bio, Inc. (UPB) is a biopharmaceutical company focused on developing innovative therapies for patients with unmet medical needs. The company operates primarily in the biopharmaceutical sector, specializing in the research and development ...
How the Company Makes Money
null...
Upstream Bio, Inc. Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
74
Positive
Cash Flow
27
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.32M | 2.85M | 2.37M | 2.38M | 1.21M |
| Gross Profit | 3.27M | 2.85M | 2.37M | 2.38M | 1.21M |
| EBITDA | -171.77M | -160.17M | -77.67M | -40.05M | -23.90M |
| Net Income | -156.76M | -143.44M | -62.81M | -20.54M | -23.87M |
Balance Sheet | |||||
| Total Assets | 318.05M | 353.77M | 481.72M | 117.20M | 18.48M |
| Cash, Cash Equivalents and Short-Term Investments | 294.58M | 341.51M | 470.45M | 109.81M | 17.05M |
| Total Debt | 1.11M | 1.27M | 1.83M | 45.00K | 94.00K |
| Total Liabilities | 14.06M | 14.00M | 11.87M | 240.32M | 124.63M |
| Stockholders Equity | 304.00M | 339.77M | 469.85M | -123.13M | -106.16M |
Cash Flow | |||||
| Free Cash Flow | -140.01M | -133.28M | -59.68M | -38.07M | -19.10M |
| Operating Cash Flow | -139.96M | -133.28M | -59.17M | -37.93M | -19.02M |
| Investing Cash Flow | 162.30M | -93.48M | -59.48M | -82.84M | -82.00K |
| Financing Cash Flow | 3.07M | 2.44M | 418.91M | 129.55M | 9.96M |
Upstream Bio, Inc. Technical Analysis
Negative
30.30
Price Trends
9.27
Negative
14.99
Negative
18.52
Negative
Market Momentum
-0.35
Positive
39.73
Neutral
26.77
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UPB, the sentiment is Negative. The current price of 30.3 is above the 20-day moving average (MA) of 8.97, above the 50-day MA of 9.27, and above the 200-day MA of 18.52, indicating a bearish trend. The MACD of -0.35 indicates Positive momentum. The RSI at 39.73 is Neutral, neither overbought nor oversold. The STOCH value of 26.77 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for UPB.
Upstream Bio, Inc. Risk Analysis
Upstream Bio, Inc. disclosed 80 risk factors in its most recent earnings report. Upstream Bio, Inc. reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Upstream Bio, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | $843.92M | -42.18 | 43.85% | ― | 68.20% | ― | |
60 Neutral | $1.42B | -5.37 | -35.89% | ― | ― | -63.41% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $317.17M | -1.33 | -35.74% | ― | 146.03% | -0.87% | |
49 Neutral | $1.20B | ― | -167.71% | ― | -100.00% | -128.73% | |
48 Neutral | $455.50M | -3.01 | -43.82% | ― | ― | ― | |
42 Neutral | $536.43M | ― | -188.82% | ― | 4.89% | 24.20% |
* Healthcare Sector Average
UPB
Upstream Bio, Inc.
8.37
-1.25
-12.99%
TBPH
Theravance Biopharma
16.37
7.07
76.02%
BCYC
Bicycle Therapeutics
4.55
-3.50
-43.48%
PRME
Prime Medicine, Inc.
2.97
1.70
133.86%
BCAX
Bicara Therapeutics Inc.
21.68
11.70
117.23%
ZBIO
Zenas BioPharma, Inc.
18.97
8.41
79.64%
Upstream Bio, Inc. Corporate Events
Private Placements and FinancingRegulatory Filings and Compliance
Upstream Bio Launches $150 Million At-The-Market Program
Neutral
Mar 26, 2026
On March 26, 2026, Upstream Bio, Inc. entered into a sales agreement with Leerink Partners LLC to establish an at-the-market equity program for its common stock. Under this arrangement, the company may, but is not obligated to, sell up to $150 mil...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.